Impact Of Rosuvastatin On Vascular Endothelial Function In H-hypertensive Rats

Objective: To investigate the prophylactic using of rosuvastatin,the expression of vascular endothelial growth factor and asymmetrical dimethylarginine in H-hypertensive rats, improves the endothelial function.A nd it is to be explored the possible mechanism of the clinical application rosuvastatin.We speculate to invest after using rosuvastatin, the effects of it to endogenous VEGF and ADMA expression.Method: In this study, male rats were divided into four groups: normal SD rats in the control group(NC group), H hypertension model group(Hcy group), H hypertensive rats were given rosuvastatin intervention group(HR group) and spontaneously hypertensive rats were given rosuvastatin intervention group(SR group).There were 8 rats of each group. H-hypertensive model using spontaneously hypertensive rats fed rat chow add 2% methionine, rosuvastatin treatment group received 10 ml / kg / d orally, the normal control group and model group H hypertensive rats fed such as the capacity of distilled water for 4 weeks. During the experiment rats were fed water freely. After four weeks, measured angular vein blood serum homocysteine, total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol. By enzyme-linked immunosorbent(Enzyme-Linked Immunosorbent Assay, ELISA) method to measure VEGF and ADMA; immunohistochemical expression was observed in the rat vascular VEGF each group. Measurement data are used( x ± s), treatment with SPSS statistical package, using one-way ANOVA analysis of four groups according to the different requirements of the above data, the mean variance between pairwise comparisons using LSD-t test when Sarkozy, two sets of data using an independent samples T-test, with α=0.05 indicate a statistically significant difference.Results:1 Before modeling the blood pressure in spontaneously hypertensive rats in each group did not differ(P> 0.05), but significantly higher than normal SD rats. 4 weeks after administration, NC group, HCY group and blood pressure before and after the treatment had no significant difference, HR group, blood pressure SR group compared with before treatment there was a significant difference(P<0.05), HR group, SR group comparison between blood pressure and HCY group, the difference was statistically significant(P<0.05).2 Homocysteine, total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol levels change: After four weeks of treatment in rats fed, HCY group and HR group blood homocysteine content higher than NC group, SR rats, confirming H hypertensive rats modeling success, The difference levels of lipid in rats was not statistically significant(P>0.05).3 Determination of serum levels of VEGF, VEGF serum content of each group had no significant difference before modeling, 4 weeks after administration, HR group, serum levels of VEGF SR group compared with before treatment There was a significant difference(P<0.05), HR group, VEGF serum content of SR group was significantly higher than NC group and HCY group, the difference was statistically significant(P<0.05).4 Determination of serum levels of ADMA, the serum ADMA content rats no significant difference before modeling, 4 weeks after administration, HR group, serum ADMA content SR group compared with before treatment There was a significant difference(P<0.05), HR group, serum ADMA content SR group of rats was significantly lower than the NC group and HCY group, the difference was statistically significant(P<0.05).5 Immunohistochemistry shows: VEGF mainly expressed in vascular endothelial cells have strong positive expression, HR group, SR group expression in endothelial within stronger than the normal control group and HCY groups.Conclusion:1 Rosuvastatin may reduce blood pressure in spontaneously hypertensive and H-hypertensive rats.2 To give rosuvastatin after statin therapy, VEGF expression is up regulated in the blood vessels, and down regulation of the expression of ADMA.3 The rosuvastatin above mechanisms may affect the H-hypertensive vascular endothelial function. Conclusions:...